Douglass Winthrop Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Douglass Winthrop Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,406	Closed	-$224K	–	241
2017 Q3	$224K	Buy	2,406 +56	+2%	+$4.95K	0.01%	235
2017 Q2	$213K	Hold	2,350	–	–	0.01%	239
2017 Q1	$206K	Sell	2,350 -760	-24%	-$67.6K	0.01%	236
2016 Q4	$258K	Hold	3,110	–	–	0.02%	208
2016 Q3	$288K	Buy	3,110 +35	+1%	+$3.3K	0.02%	202
2016 Q2	$239K	Sell	3,075 -325	-10%	-$27.6K	0.02%	218
2016 Q1	$280K	Hold	3,400	–	–	0.02%	189
2015 Q4	$356K	Hold	3,400	–	–	0.03%	181
2015 Q3	$358K	Buy	3,400 +1,400	+70%	+$187K	0.03%	185
2015 Q2	$249K	Hold	2,000	–	–	0.02%	227
2015 Q1	$249K	Buy	+2,000	New	+$212K	0.02%	227

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Douglass Winthrop Advisors's BMRN Position: Q4 2017 in Review

Douglass Winthrop Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 2,406 shares — an estimated $224K sold.

Douglass Winthrop Advisors first reported a position in BMRN in Q1 2015 and held it in 11 quarters. The position peaked at $358K in Q3 2015. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Douglass Winthrop Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Douglass Winthrop Advisors sold 2,406 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $224K.
Douglass Winthrop Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 11 quarters.
Douglass Winthrop Advisors's BioMarin Pharmaceuticals position peaked at $358K in Q3 2015.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Douglass Winthrop Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.